This webinar will be recorded live on January 30, 2024. The recording will be available within 30 days of the event date. You may pre-order the recording here.

The session will review the recent Amgen Supreme Court Decision, which found that Amgen's patent covering its cholesterol lowering drug Repatha invalid for lack of enablement. The claims of the patent are broadly directed to an antibody that binds certain epitopes on the PCSK9 enzyme. The session will involve analyzing the Supreme Court's rationale for lack of enablement and explore its impact on patenting strategies for life science discoveries more generally.